Syed Rizwanuddin Ahmad, MD, MPH, FISPE, FCP is trained in pharmacovigilance, pharmacoepidemiology and drug regulatory science. He has over 25 years of experience in civil society organizations/non-profit groups and the public sector (United States Food and Drug Administration -FDA). He is a medical graduate of Dow University of the Health Sciences; did a fellowship in clinical pharmacology and drug regulation at Georgetown University Medical Center; and has a public health degree from the Johns Hopkins Bloomberg School of Public Health.
He consults in pharmacovigilance, and pharmacoepidemiology; on issues related to drug approval; benefit-risk assessment; risk management plans; risk communication; generic drugs; poison and drug information center; medication errors; medicines policy; essential medicines; rational use of medicines; antimicrobial resistance; access to medicines; and global health. Areas of interest include active pharmacovigilance and anti-TB/HIV/AIDS/malaria drugs; causality assessment; signal identification, detection and management; training, capacity building in pharmacovigilance and strengthening of FDA-like agencies in resource-limited countries. He has provided technical assistance to national medicines regulatory agencies/Ministry of Health in countries in Asia and Africa. He has an academic appointment (Assistant Professor) at Georgetown University School of Medicine where he teaches medical students the science of rational prescribing and drug regulation. He was recently appointed Associate Professor at Rutgers School of Public Health where he will be teaching a course on pharmacovigilance and regulatory science. He has been invited to give lectures/workshops on pharmacovigilance at several international meetings.
He has 15 years’ experience (1998-2013) at the FDA where he served as a consultant to the review divisions to answer safety questions. As a member of the FDA Committee on Advanced Scientific Education, he was active in education and training activities for FDA scientists, organized seminars; training courses/workshops; and was instrumental in the launch of FDA’s first Epi for Non-Epidemiologist course. He was also on the faculty of two pharmacoepidemiology courses.
He is an active member of the International Society for Pharmacoepidemiology (ISPE) since 1991. During his more than 20 years of membership, he reviewed abstracts for the annual meetings; served as a member of several Committees (Education; Publication; and Global Development); served as a Chair; and Vice Chair of the Government and Regulatory Council; edited ISPE’s newsletter Scribe; organized/chaired/moderated several symposia/sessions during annual meetings; served on the faculty of introduction to pharmacoepidemiology course and has given introduction to pharmacovigilance lectures. In 2014, he conceived the idea for the first Vaccine Safety pre-conference course with the support of Vaccine SIG that will be offered in ICPE Boston in August 2015. In 2006, in recognition of his contributions, he was inducted as a Fellow in ISPE. In 2009, he was conferred Fellowship of the American College of Clinical Pharmacology.
His publications include 5 book chapters on spontaneous reporting/pharmacovigilance; and one on the evolution of the FDA drug approval process.